The findings from this study suggest that the identified hub genes (PARK2, CUL1, SKP1, CYC1, and ATP5A1) and the mitochondrial oxidative phosphorylation and ubiquitination-related biological pathways could serve as novel therapeutic targets for MDD. The gene discussed is PRKN; the disease is major depressive disorder.